I am a Physician Scientist dedicated to improving outcomes for patients with cancer with a focus on next gen diagnostics, target discovery and translational medicine. I was Co-leader for The Cancer Genome Atlas (TCGA) Breast Project where I established collaborations with several Genome Centers on massive parallel sequencing of breast cancer (Nature 2012, Nature 2012). With support from the NCI program “Specialized Program for the Evaluation of Cancer Signatures (SPECS)”, I co-developed the PAM50-based diagnostic platform which is now available as the Nanostring-based device “Prosigna” – approved in over 20 counties for the determination of prognosis in ER+ HER2- early-stage breast cancer (JCO 2009).    Deepening my diagnostics/discovery experience, I have been a principal investigator in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) for over a decade.  CPTAC is focused on translating proteogenomic findings into improvements in the diagnosis and treatment of common solid malignancies (Nature 2016, Nature Communications 2020, Cell 2020, Cancer Discovery 2022, Clinical Proteomics 2023). I was also an early adopter of patient-derived xenograft (PDX) research. I led the effort to generate the widely used WHIM series of patient-derived PDX models while at Washington University (Nature 2010, Cell Reports 2013, Cancer Cell 2020, Cancer Research 2023). Specific examples of therapeutic insights in breast cancer discovered through these efforts included HER2 mutation and neratinib (Cancer Discovery 2013, Clinical Cancer Research 2022), NF1 loss and binimetinib (Cancer Cell 2020) and ESR1 translocations and pralsetinib (Cancer Research 2023). I have also helped design and execute a number of Phase 1 to 3 clinical trials, with an emphasis on mechanism of action (letrozole, fulvestrant, buparlisib and palbociclib) I was principal investigator for the Baylor College of Medicine Breast Cancer SPORE, awarded in 2020.  The Baylor Breast SPORE focuses on new treatments for advanced breast cancer and continues to thrive after my departure from Baylor. Motivated by a desire to have a greater impact and to expand my investigational experience beyond breast cancer I took the position of Senior Vice President Early Oncology at AZ in early 2022. I led a large organization focused on cancer drug development; from target identification through to Phase 2 clinical trials. After leaving AZ in 2024, I am exploring leadership opportunities in precision oncology, clinical proteogenomics and investigational therapies to improve outcomes in solid tumors and to promote cancer driver discovery for novel therapeutic approaches.